{
    "nctId": "NCT02073487",
    "briefTitle": "Neoadjuvant TDM1 With Lapatinib and Abraxane Compared With Trastuzumab Plus Pertuzumab With Paclitaxel",
    "officialTitle": "Randomized Open Label PhII Trial of Neoadjuvant Trastuzumab Emtansine(Te) in Combination w/Lapatinib(L) Followed by Abraxane (A) Compared w/Trastuzumab Plus Pertuzumab Followed by Paclitaxel in Her2/Neu Over-Expressed Breast Cancer Patients",
    "overallStatus": "COMPLETED",
    "conditions": "Breast Cancer",
    "studyType": "INTERVENTIONAL",
    "phase": "PHASE2",
    "allocation": "RANDOMIZED",
    "primaryPurpose": "TREATMENT",
    "enrollmentCount": 32,
    "primaryOutcomeMeasure": "Pathological Complete Response (pCR) RCB-0 or RCB-1",
    "eligibilityCriteria": "Inclusion Criteria:\n\n* Female gender;\n* Age \u226518 years;\n* Performance Status- Eastern Cooperative Oncology Group (ECOG) 0-1\n* Histologically confirmed invasive breast cancer:\n* Primary tumor greater than 1 cm diameter, measured by clinical examination and mammography or ultrasound.\n* Any N,\n* No evidence of metastasis (M0) (isolated supra-clavicular node involvement allowed);\n* Over expression and/or amplification of HER2 in the invasive component of the primary tumor and confirmed by a certified laboratory prior to randomization.\n* Known hormone receptor status.\n* Hematopoietic status:\n* CBC not less than .75 of institutional lower limit. Absolute neutrophil count \u2265 1,5 x 10\\^9/L, Platelet count \u2265 100 x 10\\^9/L, Hemoglobin at least 9 g/dl,\n* Hepatic status:\n\nSerum total bilirubin \u2264 2 x upper limit of normal (ULN). In the case of known Gilbert's syndrome, a higher serum total bilirubin (\\< 1.5 x ULN) is allowed, Aspartate Aminotransferase (AST) and Alanine Aminotransferase (ALT) \u2264 3.5 times ULN, Alkaline phosphatase \u2264 2.5 times ULN, \u2022 Renal status: Creatinine \u2264 1.5mg/dL,\n\n\u2022 Cardiovascular: Baseline left ventricular ejection fraction (LVEF) \u00b3 \u226550% measured by echocardiography (ECHO) or Multiple Gate Acquisition (MUGA) scan,\n\n* Negative serum or urine \u03b2-hCG pregnancy test at screening for patients of childbearing potential within 2-weeks (preferably 7 days) prior to randomization.\n* Fertile patients must use effective contraception (barrier method - condoms, diaphragm - also in conjunction with spermicidal jelly, or total abstinence. Oral, injectable, or implant hormonal contraceptives are not allowed)\n* Signed informed consent form (ICF)\n* Patient accepts to make available tumor samples for submission to central laboratory to conduct translational studies as part of this protocol.\n\nExclusion Criteria:\n\n* Previous (less than 5 years) or current history of malignant neoplasms, except for curatively treated: Basal and squamous cell carcinoma of the skin; Carcinoma in situ of the cervix.\n* Patients with a prior malignancy diagnosed more than 5 years prior to randomization may enter the study.\n* Preexisting peripheral neuropathy \u2265 grade 2\n* Known history of uncontrolled or symptomatic angina, clinically significant arrhythmias, congestive heart failure, transmural myocardial infarction, uncontrolled hypertension (\u2265180/110), unstable diabetes mellitus, dyspnea at rest, or chronic therapy with oxygen;\n* Concurrent disease or condition that would make the subject inappropriate for study participation or any serious medical disorder that would interfere with the subject's safety;\n* Unresolved or unstable, serious adverse events from prior administration of another investigational drug;\n* Dementia, altered mental status, or any psychiatric condition that would prevent the understanding or rendering of ICF;\n* Malabsorption syndrome, disease significantly affecting gastrointestinal function, or resection of the stomach or small bowel. Subjects with ulcerative colitis are also excluded;\n* Concurrent neoadjuvant cancer therapy (chemotherapy, radiation therapy, immunotherapy, biologic therapy other than the trial therapies);\n* Concurrent treatment with an investigational agent or participation in another therapeutic clinical trial;\n* Known immediate or delayed hypersensitivity reaction or idiosyncrasy to drugs chemically related to trastuzumab Emtansine, trastuzumab, lapatinib, paclitaxel, abraxane or their components;\n* Pregnant or lactating women;\n* Concomitant use of CYP3A4 inhibitors or inducers\n* Other concurrent severe and/or uncontrolled concomitant medical conditions (e.g. active or uncontrolled infection, uncontrolled diabetes) that could cause unacceptable safety risks or compromise compliance with the protocol\n* Patients have an active infection and require IV or oral antibiotics.\n* Pregnant or breast-feeding women\n* Patients unwilling or unable to comply with the protocol",
    "sex": "FEMALE",
    "minimumAge": "18 Years",
    "stdAges": "ADULT, OLDER_ADULT"
}